Average Cost of Allergy Shots: What the Data Actually Shows by Payer

There is no meaningful single national average — the distribution is too wide. The most rigorous published dataset, Tkacz et al. 2021 (IBM MarketScan, n=103,207 commercially insured AIT patients), reports a mean 12-month total healthcare cost of $10,431 with a standard deviation of $16,606 for maintenance-cohort patients. Critically, that figure represents total healthcare cost including comorbidity-related spending on asthma, sinusitis, and ENT — not just SCIT line items. The per-visit Medicare-allowed amount for a maintenance shot (CPT 95117 plus amortized vial portion) is approximately $24 in 2025. At a $42 average specialist copay (KFF 2024 Employer Health Benefits Survey), a 14-visit maintenance year generates $588 in annual patient OOP — far below the $10,431 Tkacz total.

The Tkacz 2021 figure ($10,431 mean annual total healthcare cost) includes all healthcare spending for AIT patients — asthma medications, ENT visits, urgent-care encounters for allergic reactions, sinusitis antibiotics, and general medical care — not just allergy-shot line items. The SCIT-specific portion of that total is a fraction of the overall number. Importantly, Tkacz 2021 also reports that 23.9% of AIT patients never returned for their first injection after the index consultation, and those non-completing patients still incurred significant workup and testing costs. The standard deviation of $16,606 exceeds the mean, indicating a highly right-skewed distribution driven by HOPD-billed cases and high-comorbidity patients.

For a commercially insured patient at a freestanding allergist with a met deductible and a flat specialist copay, the median per-maintenance-visit patient OOP is $15–$40. The KFF 2024 Employer Health Benefits Survey reports an average specialist copay of $42; the AAOA Stachler 2020 memo cites $20 as a common copay benchmark. Over a standard 14-visit maintenance year, that generates $210–$588 in stacked copays. A Year 1 build-up of 26 weekly visits adds $390–$1,092 in build-up copays at that same range. The 75th-percentile OOP is considerably higher — Tkacz 2021 documents that approximately 20% of index AIT paid amounts exceeded $1,000, typically driven by HDHP pre-deductible exposure or HOPD billing.

Medicare's 2025 allowed amount for CPT 95117 is $11.97 — lower than the commercial carrier averages of $15.10–$18.05 per PayerPrice April 2026 transparency data. However, the patient-owed comparison flips: Medicare patients pay 20% coinsurance (~$2.40–$3.20 per 95117 visit after the deductible), whereas commercial patients pay copays of $15–$40. A maintenance year at Medicare rates generates approximately $31.76 per visit in patient coinsurance for a combined injection-plus-vial day (Case 8, PFS-anchored), versus $15–$40 in commercial copays. Medicare + Medigap patients pay $0 per visit — the most favorable patient-OOP position in the market, despite the lowest allowed amounts.

Cox, Murphey, and Hankin (Immunol Allergy Clin North Am 2020;40[1]:69-85) place the SCIT cost-effectiveness break-even versus standard pharmacotherapy at roughly 6 years after initiation, meaning the direct medical costs of a typical 3-year SCIT course do not break even purely on drug-spend comparison — the savings come from comorbidity reduction and quality-adjusted life-year gains. Hankin 2013 (J Allergy Clin Immunol 2013;131[4]:1084-91) found 18-month total healthcare cost 38% lower in adult SCIT patients ($6,637 vs $10,644 in controls), but that advantage includes reduced urgent-care and asthma spending, not just a comparison of SCIT costs versus antihistamine costs. Brand-name nasal corticosteroids plus antihistamines run $400–$1,200/year retail at persistent year-round dosing.

Year 1 is the most expensive year because the build-up phase concentrates approximately 26 weekly visits into the first 6 months before transitioning to maintenance. Per Cox 2011 Practice Parameter Third Update (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55), Year 1 totals approximately 39 visits (26 build-up plus 13 early maintenance). At a $42 average specialist copay (KFF 2024), 39 visits generate $1,638 in stacked copays before vial charges. Add two vial-preparation events at $50–$100 insured share each and Year 1 commercial OOP averages $1,700–$2,000. At Medicare-allowed amounts, Year 1 total (95117 × 39 plus 95165 × ~60 doses) is approximately $1,302 allowed before deductible adjustment.

Tkacz et al. 2021 (Curr Med Res Opin 2021;37[6]:957-965, IBM MarketScan n=103,207) found that 23.9% of patients who had an index allergen immunotherapy consultation never returned for their first injection. This drop-off is clinically and financially significant: those patients incurred testing and consultation costs with no immunotherapy benefit. Among patients who do start injections, completion to the recommended 3–5 year maintenance course is variable; the build-up phase, with its weekly visit requirement and stacking copay burden, is where most non-completion occurs. At $42 per copay and 26 weekly build-up visits, a patient who quits after 3 months has spent $504 in copays and accrued an initial vial cost with no lasting disease modification.